Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
The company is abandoning ovarian and bladder, but still sees a path in endometrial cancer.
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
The company is stepping back in second-line breast cancer.
